Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
 to The Nasdaq Stock Market - EconoTimes)
NEW YORK, April 19, 2018 -- MorphoSys AG (Nasdaq:MOR), a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
|
|||||
Together with its partners, MorphoSys has aided in the development of more than 100 therapeutic product candidates based on its proprietary technology platforms and leadership in the field of therapeutic antibody discovery, generation and engineering. With more than 28 product candidates in clinical development, MorphoSys boasts a large and diverse pipeline, composed of both proprietary and partnered programs, in multiple therapeutic areas and across all development phases of drug candidates.
“MorphoSys has a proven track record of applying its proprietary technology to developing innovative therapeutic candidates,” said Dr. Simon E. Moroney, D. Phil, Co-founder & Chief Executive Officer of MorphoSys. “The recent successful launch of Tremfya® by our partner Janssen was an important milestone for MorphoSys, as it was the first market introduction of a therapeutic agent made using our proprietary technology. Our focus is now on MOR208, a product candidate for aggressive lymphoma, which received FDA breakthrough designation in 2017. Our Nasdaq listing is an important part of our plan to advance the development of MOR208 in preparation for its potential commercialization in the United States. We are now well-positioned to expand our footprint in the U.S. and to continue to build a fully-integrated biopharmaceutical company.”
“MorphoSys’s rich heritage in antibody discovery and development, paired with its proprietary technologies, truly sets it apart as a leader in the biopharmaceutical industry,” said Nelson Griggs, President, Nasdaq Stock Exchange. “We are excited to welcome MorphoSys to the Nasdaq Stock Exchange and support the company’s continued success as it works to improve the lives of patients suffering from serious diseases.”
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion. To learn more, visit: http://business.nasdaq.com
Media Relations Contact:
| |
- NDAQG -
A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/c3262710-3df1-4daa-b6e0-0a6ed83cd991
